Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling (Q40444417)

20 September 2017

title

Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling (English)

1 reference

20 September 2017

4

Matt van de Rijn

1 reference

20 September 2017

3

Shirley Zhu

1 reference

20 September 2017

1

C Blake Gilks

1 reference

20 September 2017

author name string

Barbara C Vanderhyden

series ordinal

2

1 reference

20 September 2017

Teri A Longacre

series ordinal

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

96

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

684-694

1 reference

Classification and Staging of Malignant Tumours in the Female Pelvis

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Microsatellite analysis in serous tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Tumor Recurrence in Stage I Ovarian Serous Neoplasms of Low Malignant Potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

A gene-expression signature as a predictor of survival in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Gene expression profiling predicts clinical outcome of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Diversity of gene expression in adenocarcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular characterisation of soft tissue tumours: a gene expression study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Gene expression patterns in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Cluster analysis and display of genome-wide expression patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Significance analysis of microarrays applied to the ionizing radiation response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Gene expression in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Expression of cell cycle regulators p57KIP2, cyclin D1, and cyclin E in epithelial ovarian tumors and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

DNA microarrays for assessing ovarian cancer gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Update on the role of topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Molecular aspects of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2004.11.039

10.1016/J.YGYNO.2004.11.039

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference